MoU signed for commercial production of indigenously developed vaccine ‘Lumpi-ProVac’
Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease, which illicit protection for about one year
Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease, which illicit protection for about one year
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.
The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents
The funds raised through the issue will be utilised to meet the working capital requirements to fund the company's expansion plans, entering new geographies and for general corporate purposes
The company will reduce wastage substantially, increase productivity, enhance environmental consciousness, save energy, optimally use natural resources, and expand its market penetration
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
The acquisition is for an enterprise value of Rs. 218 crores
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
Government Ayurveda College & Hospital will include an infrastructure for the College and a 100 bedded hospital, hostel block for students and staff quarters.
Subscribe To Our Newsletter & Stay Updated